• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大多数非劣效性试验并非旨在保留活性对照治疗效果。

Most noninferiority trials were not designed to preserve active comparator treatment effects.

机构信息

Schulich School of Medicine and Dentistry, 1151 Richmond St, London, Ontario N6A 5C1, Canada.

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, 90 High Holborn, London WC1V 6LJ, UK.

出版信息

J Clin Epidemiol. 2019 Jun;110:82-89. doi: 10.1016/j.jclinepi.2019.03.003. Epub 2019 Mar 8.

DOI:10.1016/j.jclinepi.2019.03.003
PMID:30858020
Abstract

OBJECTIVES

To evaluate whether noninferiority trials are designed to adequately preserve the historical treatment effect of their active comparators.

STUDY DESIGN AND SETTING

We reviewed 162 noninferiority trials published in high-impact medical journals. We assessed whether trials were designed to ensure that interventions could only be declared noninferior if they preserved at least 50% of the active comparator's historical treatment effect.

RESULTS

Only 25 of 162 trials (15%) were designed so that interventions could only be declared noninferior if they preserved at least 50% of the active comparator's historical treatment effect. Most trials did not provide evidence that the active comparator was effective (n = 101), provided inadequate evidence (n = 18), or used a noninferiority margin that was too wide (n = 18). In a subset of 61 noninferiority trials which referenced a prior randomized trial or meta-analysis evaluating the active comparator, only 25 (41%) used a noninferiority margin small enough to preserve at least 50% of the active comparator's treatment effect. Overall, 14 of 162 noninferiority trials (9%) would have allowed the intervention to be declared noninferior even if it was worse than either placebo or another historical control.

CONCLUSION

Most noninferiority trials published in major medical journals could allow erroneous declarations of noninferiority.

摘要

目的

评估非劣效性试验是否旨在充分保留其活性对照物的历史治疗效果。

研究设计和设置

我们回顾了在高影响力医学期刊上发表的 162 项非劣效性试验。我们评估了试验的设计是否确保只有在干预措施至少保留活性对照物历史治疗效果的 50%时,才能宣布非劣效性。

结果

只有 162 项试验中的 25 项(15%)设计为只有在干预措施至少保留活性对照物历史治疗效果的 50%时,才能宣布非劣效性。大多数试验没有提供活性对照物有效的证据(n=101),提供的证据不足(n=18),或者使用的非劣效性边界太宽(n=18)。在 61 项参考了先前评估活性对照物的随机试验或荟萃分析的非劣效性试验的子集中,只有 25 项(41%)使用的非劣效性边界足够小,足以保留活性对照物治疗效果的至少 50%。总体而言,162 项非劣效性试验中的 14 项(9%)即使干预措施比安慰剂或另一个历史对照物差,也允许宣布非劣效性。

结论

大多数发表在主要医学期刊上的非劣效性试验可能允许错误地宣布非劣效性。

相似文献

1
Most noninferiority trials were not designed to preserve active comparator treatment effects.大多数非劣效性试验并非旨在保留活性对照治疗效果。
J Clin Epidemiol. 2019 Jun;110:82-89. doi: 10.1016/j.jclinepi.2019.03.003. Epub 2019 Mar 8.
2
Comparative effectiveness clinical trials in psychiatry: superiority, noninferiority, and the role of active comparators.精神病学中的比较有效性临床试验:优越性、非劣效性以及阳性对照的作用。
J Clin Psychiatry. 2011 Oct;72(10):1344-9. doi: 10.4088/JCP.10m06089whi.
3
Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate.使用单一的非劣效性边界或保留分数来涵盖整个药理学类别被认为是不恰当的。
J Clin Epidemiol. 2018 Dec;104:15-23. doi: 10.1016/j.jclinepi.2018.07.004. Epub 2018 Aug 25.
4
Defining the noninferiority margin and analysing noninferiority: An overview.定义非劣效性界值并分析非劣效性:概述。
Br J Clin Pharmacol. 2017 Aug;83(8):1636-1642. doi: 10.1111/bcp.13280. Epub 2017 Apr 6.
5
Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals.药物研发中的非劣效性试验设计:心血管医疗保健专业人员入门指南。
Am J Cardiovasc Drugs. 2020 Jun;20(3):229-238. doi: 10.1007/s40256-019-00378-w.
6
Some issues for the evaluation of noninferiority trials.非劣效性试验评估的一些问题。
J Comp Eff Res. 2018 Sep;7(9):835-843. doi: 10.2217/cer-2018-0035. Epub 2018 Sep 7.
7
Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine.了解心血管医学中非劣效性试验的优缺点。
Can J Cardiol. 2021 Sep;37(9):1378-1393. doi: 10.1016/j.cjca.2021.05.017. Epub 2021 Jun 9.
8
Methodological quality of oncology noninferiority clinical trials.肿瘤非劣效性临床试验的方法学质量。
Crit Rev Oncol Hematol. 2020 May;149:102938. doi: 10.1016/j.critrevonc.2020.102938. Epub 2020 Mar 5.
9
Quality of reporting of noninferiority and equivalence randomized trials.非劣效性和等效性随机试验的报告质量
JAMA. 2006 Mar 8;295(10):1147-51. doi: 10.1001/jama.295.10.1147.
10
Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals.高质量医学期刊发表的优效性和非劣效性随机临床试验的方案依从率。
Clin Trials. 2020 Oct;17(5):552-559. doi: 10.1177/1740774520941428. Epub 2020 Jul 15.

引用本文的文献

1
Applying the Estimands Framework to Non-Inferiority Trials: Guidance on Choice of Hypothetical Estimands for Non-Adherence and Comparison of Estimation Methods.将估计量框架应用于非劣效性试验:关于非依从性假设估计量选择及估计方法比较的指南
Stat Med. 2025 Feb 28;44(5):e10348. doi: 10.1002/sim.10348.
2
Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.沃诺拉赞与兰索拉唑治疗糜烂性食管炎的疗效比较:一项随机对照试验的系统评价和荟萃分析。
Indian J Gastroenterol. 2023 Aug;42(4):475-484. doi: 10.1007/s12664-023-01384-2. Epub 2023 Jul 7.
3
Reporting quality of randomized controlled trials evaluating non-vitamin K oral anticoagulants in atrial fibrillation: a systematic review.
评估非维生素 K 口服抗凝剂在心房颤动中疗效的随机对照试验报告质量:系统评价。
BMC Cardiovasc Disord. 2023 May 3;23(1):229. doi: 10.1186/s12872-023-03258-z.
4
How do we know a treatment is good enough? A survey of non-inferiority trials.我们如何知道一种治疗方法足够好?一项非劣效性试验调查。
Trials. 2022 Dec 16;23(1):1021. doi: 10.1186/s13063-022-06911-8.
5
Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies.比较效果研究:IBD 治疗领域航行的路线图。
J Clin Med. 2022 Nov 13;11(22):6717. doi: 10.3390/jcm11226717.
6
Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.托珠单抗、沙利鲁单抗和巴瑞替尼对 COVID-19 住院患者接受皮质类固醇治疗的死亡率的影响:系统评价和荟萃分析。
Clin Microbiol Infect. 2023 Jan;29(1):13-21. doi: 10.1016/j.cmi.2022.07.008. Epub 2022 Jul 19.
7
Perceived acceptable uncertainty regarding comparability of endovascular treatment alone versus intravenous thrombolysis plus endovascular treatment.对单纯血管内治疗与静脉溶栓联合血管内治疗的可比性的可接受不确定性的感知。
J Neurointerv Surg. 2023 Mar;15(3):227-232. doi: 10.1136/neurintsurg-2022-018665. Epub 2022 Mar 1.
8
Patient and public involvement in numerical aspects of trials (PoINT): exploring patient and public partners experiences and identifying stakeholder priorities.患者和公众参与试验的数值方面(PoINT):探索患者和公众合作伙伴的经验并确定利益相关者的优先事项。
Trials. 2021 Jul 28;22(1):499. doi: 10.1186/s13063-021-05451-x.
9
Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer.Meta-analysis 评估非劣效性:以乳腺癌和前列腺癌的分割放射治疗为例。
Sci Rep. 2020 Sep 22;10(1):15415. doi: 10.1038/s41598-020-72088-2.
10
Head-to-head trials in inflammatory bowel disease: past, present and future.炎症性肠病的头对头试验:过去、现在和未来。
Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):365-376. doi: 10.1038/s41575-020-0293-9. Epub 2020 Apr 17.